Aurobindo Pharma Ltd (AUROPHARMA) Q1 FY27 Results Analysis: PAT Jumps 25.2%, Gross Margin Expands 160 bps

Aurobindo Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 9,150.35 Cr (+16.30% YoY) and PAT growth of +25.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Auropharma delivered a solid Q1 with 16.3% YoY revenue growth and 25.2% PAT growth, driven by favourable forex tailwinds, Europe formulations momentum, and Pen-G turning EBITDA-positive. Gross margins expanded 160 bps YoY to 60.4%, while the recently closed Lannett acquisition and ongoing Pen-G/biosimilar ramp-up provide near-term catalysts toward the stated FY27 EBITDA margin target of >21%.

Key Investment Insights

Key Positives

• Revenue grew 16.3% YoY to Rs.9,150.35 Cr, the fastest quarterly clip in several periods
• PAT-to-owners grew 25.2% YoY to Rs.1,032.56 Cr, outpacing revenue growth
• Gross margin expanded 160 bps YoY to 60.4%, the highest in the trailing year
• EBITDA grew 17.3% YoY to Rs.1,880.96 Cr, with margin improving to 20.56% from 20.38% a year ago
• Normalized PAT (excluding exceptional items) grew 28.5% YoY to Rs.1,059.40 Cr
• Europe formulations momentum continues, having achieved €1 Bn annual revenue in FY26 (up 23.4% YoY)
• Pen-G production is generating positive EBITDA, contributing to API growth

Risk Factors

• Employee benefits expense grew 20.5% YoY (16.2% of revenue vs 15.6% a year ago), driven by annual increments and headcount additions
• Effective Tax Rate jumped to 31.88% from 28.65% QoQ, reverting to year-ago level
• Standalone revenue declined 1.71% YoY, reflecting the shift where subsidiary operations now drive group growth